Dymon Asia Capital Singapore PTE. LTD. Has $2.05 Million Stake in IQVIA Holdings Inc. $IQV

Dymon Asia Capital Singapore PTE. LTD. grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 97.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,000 shares of the medical research company’s stock after acquiring an additional 6,400 shares during the period. IQVIA comprises about 0.3% of Dymon Asia Capital Singapore PTE. LTD.’s portfolio, making the stock its 16th largest holding. Dymon Asia Capital Singapore PTE. LTD.’s holdings in IQVIA were worth $2,049,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Clal Insurance Enterprises Holdings Ltd grew its holdings in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after purchasing an additional 131 shares during the period. Trust Co. of Toledo NA OH acquired a new stake in shares of IQVIA in the second quarter valued at approximately $39,000. J.Safra Asset Management Corp boosted its stake in shares of IQVIA by 208.6% during the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after acquiring an additional 169 shares during the period. Rothschild Investment LLC increased its holdings in shares of IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after acquiring an additional 124 shares during the last quarter. Finally, NewSquare Capital LLC raised its stake in IQVIA by 185.3% in the 2nd quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 189 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Price Performance

IQVIA stock opened at $218.20 on Wednesday. The stock’s fifty day moving average price is $215.90 and its two-hundred day moving average price is $188.23. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $234.29. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The firm has a market cap of $37.16 billion, a PE ratio of 29.93, a price-to-earnings-growth ratio of 2.51 and a beta of 1.37.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same period in the prior year, the company posted $2.84 EPS. The company’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Robert W. Baird set a $258.00 price objective on shares of IQVIA and gave the company an “outperform” rating in a report on Wednesday, October 29th. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and upped their price target for the company from $195.00 to $235.00 in a research note on Thursday, October 9th. Stifel Nicolaus raised their price objective on shares of IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Evercore ISI upped their target price on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research report on Wednesday, October 8th. Finally, BMO Capital Markets initiated coverage on IQVIA in a report on Thursday, November 13th. They set an “outperform” rating and a $260.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $241.44.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.